¼¼°èÀÇ ¿ø·áÀǾàǰ(API) ½ÃÀå
Active Pharmaceutical Ingredients (API)
»óǰÄÚµå : 1760915
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 727 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,101,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,303,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¿ø·áÀǾàǰ(API) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 3,585¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 2,481¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¿ø·áÀǾàǰ(API) ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 6.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 3,585¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Çõ½ÅÀû ºÎ¹®Àº CAGR 6.0%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2,408¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¦³×¸¯ ÀǾàǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 6.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 773¾ï ´Þ·¯, Áß±¹Àº CAGR 6.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¿ø·áÀǾàǰ(API) ½ÃÀåÀº 2024³â¿¡ 773¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 519¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.6%·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 5.6%¿Í 6.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.6%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¿ø·áÀǾàǰ(API) ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿ø·áÀǾàǰ(API)Àº ÀǵµÇÑ Ä¡·á È¿°ú¸¦ ³»´Â ÀǾàǰÀÇ Áß¿äÇÑ ±¸¼º ¿ä¼ÒÀÔ´Ï´Ù. API´Â õ¿¬ À¯·¡¿Í ½ÇÇè½Ç ÇÕ¼ºÀ¸·Î ³ª´µ¸ç, ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀ» ÃæÁ·½ÃÄÑ¾ß ÇÏ´Â µî ´Ù¾çÇÑ È­ÇÐÀû, »ý¹°ÇÐÀû °øÁ¤À» ÅëÇØ Á¦Á¶µË´Ï´Ù. ¿ø·áÀǾàǰÀÇ Á¦Á¶¿¡´Â È­ÇÐ ÇÕ¼º, ¹ßÈ¿, ÀçÁ¶ÇÕ DNA ±â¼ú, õ¿¬¹°·ÎºÎÅÍÀÇ ºÐ¸® µî º¹ÀâÇÑ °øÁ¤ÀÌ Æ÷ÇԵǸç, ÀÌ´Â ÀǾàǰ Á¦Á¶ÀÇ Áß¿äÇÑ Ãø¸éÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¿ø·áÀǾàǰÀº Á¤Á¦, ĸ½¶Á¦, ÁÖ»çÁ¦, ¿Ü¿ëÁ¦ µî ´Ù¾çÇÑ Á¦Çü¿¡ »ç¿ëµË´Ï´Ù. °¨¿°À̳ª ÅëÁõ°ú °°Àº ÀϹÝÀûÀÎ ÁúȯºÎÅÍ ´ç´¢º´, ¾Ï, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼ºÁúȯ±îÁö ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ¿ø·áÀǾàǰÀÇ Ç°Áú°ú ¼øµµ´Â ÃÖÁ¾ ÀǾàǰÀÇ ¾ÈÀü¼º°ú À¯È¿¼º¿¡ Á÷Á¢ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®¿¡ ¾ö°ÝÇÑ Ç°Áú °ü¸®¿Í ÀûÁ¤ Á¦Á¶ ±âÁØ(GMP) Áؼö°¡ ÇÊ¿äÇÕ´Ï´Ù. Á¦¾à¾÷°è´Â ½Å¾à °³¹ß ¹× ±âÁ¸ Ä¡·á¹ý °³¼±¿¡ ÀÖ¾î ¿ø·áÀǾàǰ¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖÀ¸¸ç, ¿ø·áÀǾàǰÀº Çö´ë ÀÇÇÐÀÇ ÇÙ½ÉÀÔ´Ï´Ù.

¿ø·áÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í È¿°úÀûÀ̰í Çõ½ÅÀûÀÎ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÁÖ¿ä ÃËÁø¿äÀÎÀ̸ç, API Á¦Á¶ °øÁ¤ÀÇ ±â¼ú ¹ßÀüÀº »ý»ê È¿À²À» ³ôÀÌ°í ºñ¿ëÀ» Àý°¨ÇÏ¸ç ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ ¿ø·áÀǾàǰ Á¦Á¶¸¦ Àü¹® Á¦Á¶¾÷ü¿¡ À§Å¹ÇÏ´Â Ãß¼¼°¡ °­È­µÇ°í ÀÖ´Â °Íµµ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀǾàǰÀÇ Ç°Áú°ú ¾ÈÀü¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ¸·Î ÀÎÇØ Á¦¾à»çµéÀÌ °íǰÁú ¿ø·áÀǾàǰ »ý»ê¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰÀÇ ºÎ»ó°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀüÀº ÷´Ü ¿ø·áÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖÀ¸¸ç, ÀÌ´Â Á¦¾à »ê¾÷ÀÇ ¿ªµ¿ÀûÀ̰í ÁøÈ­Çϴ Ư¼ºÀ» ´õ¿í ºÎ°¢½Ã۰í ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(Çõ½Å, Á¦³×¸¯), ÇÕ¼º(ÇÕ¼º, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö), ¿ëµµ(½ÉÇ÷°üÁúȯ, ³»ºÐºñ, ÁßÃ߽Űæ°è, Á¾¾ç, ¼ÒÈ­±â, Á¤Çü¿Ü°ú, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 266°³»ç)

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Active Pharmaceutical Ingredients (API) Market to Reach US$358.5 Billion by 2030

The global market for Active Pharmaceutical Ingredients (API) estimated at US$248.1 Billion in the year 2024, is expected to reach US$358.5 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Innovative, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$240.8 Billion by the end of the analysis period. Growth in the Generic segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$77.3 Billion While China is Forecast to Grow at 6.6% CAGR

The Active Pharmaceutical Ingredients (API) market in the U.S. is estimated at US$77.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$51.9 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.6% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Active Pharmaceutical Ingredients (API) Market - Key Trends & Drivers Summarized

Active Pharmaceutical Ingredients (APIs) are the critical components in pharmaceutical products that produce the intended therapeutic effects. These innovative and generic ingredients are responsible for the drug's efficacy and are manufactured through various chemical and biological processes. APIs can be derived from natural sources or synthesized in laboratories, and they must meet stringent regulatory standards to ensure safety and effectiveness. The production of APIs involves complex processes, including chemical synthesis, fermentation, recombinant DNA technology, and isolation from natural sources, making it a crucial aspect of pharmaceutical manufacturing.

APIs are used in a wide range of pharmaceutical formulations, including tablets, capsules, injectables, and topical preparations. They are essential in the treatment of numerous conditions, ranging from common ailments like infections and pain to chronic diseases such as diabetes, cancer, and cardiovascular disorders, among others. The quality and purity of APIs directly impact the safety and efficacy of the final pharmaceutical product, necessitating rigorous quality control and adherence to Good Manufacturing Practices (GMP). The pharmaceutical industry relies heavily on APIs to develop new drugs and improve existing treatments, making them a cornerstone of modern medicine.

The growth in the active pharmaceutical ingredients market is driven by several factors. Increasing prevalence of chronic diseases and the rising demand for effective and innovative medications are major drivers. Technological advancements in API manufacturing processes have enhanced production efficiency and reduced costs, supporting market expansion. The growing trend towards outsourcing API production to specialized manufacturers, particularly in emerging markets, has also contributed to growth. Additionally, stringent regulatory requirements for drug quality and safety are pushing pharmaceutical companies to invest in high-quality API production. The rise of biopharmaceuticals and the development of personalized medicine are further propelling the demand for advanced APIs, underscoring the dynamic and evolving nature of the pharmaceutical industry.

SCOPE OF STUDY:

The report analyzes the Active Pharmaceutical Ingredients (API) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Innovative, Generic); Synthesis (Synthetic, Biotech); Application (Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic, Other Applications)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 266 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â